Malignant Hypertension

Article written and reviewed by Dr Luca Moretti

Malignant hypertension is a rare but extremely severe form of arterial hypertension, with a prevalence of about 1% among hypertensive patients. It is characterized by a rapid and sustained increase in blood pressure, with persistently elevated values above 180 mmHg systolic and 120 mmHg diastolic, similar to those seen in uncomplicated hypertensive crises. However, malignant hypertension is particularly dangerous because it rapidly leads to irreversible organ damage and significantly increases the risk of complicated hypertensive crises.

Pathogenesis and Pathophysiological Mechanisms

The pathogenesis of malignant hypertension is not fully understood, but it is believed to involve a combination of genetic, neurohormonal, and vascular factors. Studies suggest that certain genetic mutations may lead to excessive activation of the renin-angiotensin-aldosterone system (RAAS), resulting in increased production of aldosterone and renin.
This causes systemic vasoconstriction and retention of sodium and water, with a progressive rise in blood pressure. Chronic elevation of blood pressure triggers endothelial injury and microvascular dysfunction, manifested as:

• Arteriolar thickening and fibrosis: proliferation of the tunica media and collagen accumulation lead to loss of vascular compliance.
• Fibrinoid necrosis: a characteristic feature of malignant hypertension, with destruction of the vascular wall and loss of vessel integrity.
• Impaired blood flow autoregulation: especially at the cerebral, renal and cardiac level, leading to ischemia and progressive organ damage.

Clinical Manifestations

Malignant hypertension can affect various target organs, resulting in a varied clinical picture. The most common symptoms are due to increased hydrostatic pressure in the capillaries and the consequent dysfunction of the affected organs:

• Central Nervous System: increased blood flow to the brain leads to a loss of cerebral autoregulation, resulting in massive cerebral vasodilation, cerebral edema, and increased intracranial pressure. Symptoms include:
  • Severe and persistent headache, typically throbbing and located in the occipital region.
  • Visual disturbances, including blurred vision, scotomas, and temporary blindness due to papilledema.
  • Nausea and vomiting, often associated with increased intracranial pressure.
  • Altered mental status, with confusion, irritability, and in severe cases seizures and coma.
• Heart and Circulation: the increased pressure load imposes hemodynamic stress on the heart, which must work against high peripheral resistance. This can lead to:
  • Congestive heart failure, with acute pulmonary edema, paroxysmal nocturnal dyspnea, and exercise intolerance.
  • Left ventricular hypertrophy, with progressive myocardial stiffness and tendency to diastolic dysfunction.
  • Arrhythmias, due to reduced coronary reserve and increased myocardial oxygen consumption.
• Kidneys and Urinary System: malignant hypertension is one of the main causes of rapidly progressive renal failure. At the renal level, there is an aggressive form of malignant hypertensive nephroangiosclerosis, characterized by:
  • Significant proteinuria, indicating advanced glomerular damage.
  • Microscopic hematuria, due to glomerular basement membrane injury.
  • Rapid reduction in glomerular filtration rate, progressing toward end-stage renal failure.

Malignant hypertension is strongly associated with the risk of complicated hypertensive crises, which occur when excessively high blood pressure leads to acute organ damage.

The most serious complications include:

• Ischemic or hemorrhagic stroke, due to rupture of fragile cerebral arterioles.
• Myocardial infarction, due to imbalance between oxygen supply and demand.
• Aortic dissection, particularly in patients with severe chronic hypertension.
• Acute pulmonary edema, with severe respiratory failure.

Treatment of Malignant Hypertension

The treatment of malignant hypertension is aggressive but controlled, aiming to lower blood pressure without causing hypoperfusion. The initial therapeutic target is to reduce diastolic pressure to 95-110 mmHg within the first 24-48 hours.
The therapeutic approach varies depending on the presence or absence of acute organ damage.
In the case of a hypertensive emergency (acute organ damage), parenteral drugs such as Sodium nitroprusside, a powerful vasodilator for rapid blood pressure control; Fenoldopam, a selective vasodilator (D1 agonist) useful in patients with renal insufficiency; Labetalol, effective in lowering blood pressure without excessive reflex tachycardia; and Nicardipine, a long-acting calcium channel blocker useful in patients with cerebral damage, are used.
In the case of a hypertensive urgency (without acute organ damage), oral drugs such as ACE inhibitors and sartans can be used to reduce the renal pressure load; beta-blockers for controlling the adrenergic response; and calcium channel blockers to reduce peripheral vascular resistance.

Conclusion

Malignant hypertension carries a high mortality rate if not treated promptly. Early recognition and aggressive but controlled management of blood pressure are essential to prevent irreversible organ damage. The therapeutic approach must be individualized, with particular attention to balancing pressure reduction and maintaining adequate perfusion of vital organs.

References
1. Schetz M, et al. Fenoldopam for the prevention of acute kidney injury: a systematic review and meta-analysis. Critical Care. 2023;27(1):52-65.
2. James PA, et al. Management of Hypertensive Emergencies and Malignant Hypertension. Journal of Clinical Hypertension. 2022;24(8):1123-1138.
3. Patel KK, et al. Hypertensive Crisis: Diagnosis and Management Strategies. Current Hypertension Reports. 2021;23(5):33-45.
4. Verdecchia P, et al. Impact of Renin-Angiotensin System Inhibitors on Hypertensive Nephropathy. Journal of Nephrology. 2020;33(7):1029-1042.
5. Chrysant SG, et al. Pathophysiology and Clinical Management of Malignant Hypertension. American Journal of Medicine. 2019;132(6):667-679.
6. Mancia G, et al. 2023 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension. 2023;41(6):982-1055.
7. Vasan RS, et al. Malignant Hypertension: Pathogenesis, Diagnosis, and Management. New England Journal of Medicine. 2021;384(8):769-778.
8. Williams B, et al. Hypertensive Emergencies and Urgencies: Clinical Practice Update. The Lancet. 2021;398(10310):1207-1219.
9. Whelton PK, et al. 2023 Guidelines for the Management of Hypertension. J Am Coll Cardiol. 2023;81(7):e93-e226.
10. Pisani A, et al. Renal involvement in malignant hypertension: diagnosis and therapy. Kidney International. 2019;96(3):549-560.